StockNews.com initiated coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Free Report) in a report published on Tuesday. The firm issued a sell rating on the biotechnology company’s stock.
Genocea Biosciences Stock Performance
The firm has a market cap of $6,000.00, a P/E ratio of 0.00 and a beta of 1.61. Genocea Biosciences has a 12 month low of $0.00 and a 12 month high of $0.00. The company has a quick ratio of 1.35, a current ratio of 1.35 and a debt-to-equity ratio of 0.24.
Genocea Biosciences Company Profile
Read More
- Five stocks we like better than Genocea Biosciences
- 3 Healthcare Dividend Stocks to Buy
- When Is the Best Time to Invest in Mutual Funds?
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Is NVIDIA Stock in a Correction or Consolidation?
- With Risk Tolerance, One Size Does Not Fit All
- 3 Oversold Stocks with Big RSI Rebound Potential
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.